2[1]Unger Unger J,Fredrickson L A primer or intensive diabetes management and insulin pump therapy.Primary Care Rep,1997,3:9-18.
3[2]Bruce B,Richard W,David B,et al.Comparison of insulin aspart with buffered regular insulin and insulin lispro in contions subctancous insulin infusion.Diabetes care,2002,25:439-333.
4[3]Linkeschova R,Baoul M,Bott U,et al.Less severe hypoglycemia better metabolic control and improve quality of life in Type 1 diabetes Mellituswith continuous subcutaneous insulin infusion (CS Ⅱ) therapy,an observational study of 100 consecutive patients followed for a mean of 2 years.Diabetes Med,2002,17 (9):746-756.
5[7]Lepore M,Pampanelli S,Fanelli C,et al.Pharmacokinetics and pharmaco dynamics of subcutaneous injection of long acting human insuli analog glargine,NPH insulin and IJltralente human insulin and continuous subcutaneous infusion of insulin lispre.Diabetes 2000,49:2142-2148.
6史美甫 郭涛.精编临床用药必备[M].北京:中国科学技术出版社,2003.713.
7Janka HU,Plewe G,Riddle MC,et al.Comparison of basal insulin added to oralagents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,28 (2):254-259.
8Rosenstock J,Dailey G,Massi-Benedetti M,et al.Reduced hypoglycemia risk with insulin glararine:a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes[J].Diabetes Care,2005,28 (4):950-955.
9Kurtzhals P,Schaffer L,Sorensen A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J].Diabetes,2000,49(6):999 -1005.
10Bethel MA,Feinglos MN.Basal insulin therapy in type 2 diabetes[J].Am Board Fam Pract,2005,18 (3):199 -204.
